First Eagle Investment Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

First Eagle Investment Management’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-219,420	Closed	-$507K	–	188
2018 Q2	$507K	Hold	219,420	–	–	﹤0.01%	162
2018 Q1	$698K	Hold	219,420	–	–	﹤0.01%	162
2017 Q4	$900K	Hold	219,420	–	–	﹤0.01%	231
2017 Q3	$992K	Hold	219,420	–	–	﹤0.01%	245
2017 Q2	$731K	Buy	219,420 +60,000	+38%	+$249K	﹤0.01%	228
2017 Q1	$1.47M	Sell	159,420 -70,980	-31%	-$623K	﹤0.01%	209
2016 Q4	$1.78M	Hold	230,400	–	–	﹤0.01%	202
2016 Q3	$2.63M	Buy	230,400 +153,030	+198%	+$1.78M	0.01%	209
2016 Q2	$952K	Sell	77,370 -107,060	-58%	-$1.3M	﹤0.01%	252
2016 Q1	$1.86M	Buy	+184,430	New	+$2.17M	﹤0.01%	210

Other funds holding OMED

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

First Eagle Investment Management's OMED Position: Q3 2018 in Review

First Eagle Investment Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 219,420 shares — an estimated $507K sold.

First Eagle Investment Management first reported a position in OMED in Q1 2016 and held it in 10 quarters. The position peaked at $2.63M in Q3 2016. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

First Eagle Investment Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
First Eagle Investment Management sold 219,420 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $507K.
First Eagle Investment Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2016 and held it in 10 quarters.
First Eagle Investment Management's OncoMed Pharmaceuticals, Inc. position peaked at $2.63M in Q3 2016.
54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on First Eagle Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.